Advanced Search
Current and Breaking News for Professionals, Consumers and Media

Click here to learn how to advertise on this site and for ad rates.

Cancer Issues Author: Staff Editor Last Updated: Feb 15, 2017 - 7:36:50 PM

Genome Analysis Helps Keep Deadly Brain Cancer at Bay for Five Years

By Staff Editor
Feb 15, 2017 - 7:31:57 PM

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust

Email this article
 Printer friendly page

( - New Haven, Conn.—An analysis of a patient’s deadly brain tumor helped doctors at Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine.

The median survival rate for patients with glioblastoma multiform (GBM) is only 15 months, but three separate genomic analyses of the tumor identified new mutations that allowed doctors to adjust treatment and keep the patient alive for over five years, through two recurrences of the cancer.

“We were able to identify the molecular profile at each recurrence,” said Dr. Murat Günel, chair and the Nixdorff-German Professor in the Department of Neurosurgery, researcher with Yale Cancer Center, and senior author of the paper. “The molecular make-up of the cancer changed after each treatment and with time, but we were able to adjust treatments based on those profiles.”

For instance, the last genomic analysis revealed mutations of the cancer — under selective pressure from targeted therapies — had increased 30-fold, making the patient a good candidate for immunotherapy. Although there was an initial response, the cancer ultimately progressed.

The researchers were able to extend the findings on this case to more than 100 other GBM cases, leading to the observation that most GBMs change their genomic profile during therapy. “These findings have significant implications for precision treatment of these tumors” said Dr. Zeynep Erson Omay, the first author of the study and a research scientist in neurosurgery. “We now do a genetic analysis on every glioma surgically removed at Smilow Cancer Hospital during each recurrence or progression, comparing the molecular genomic profile to the original cancer to make treatment decisions.”

With new drugs available, there is hope that “we will soon start to see real changes in patient outcomes,” Gunel said.

Other Yale authors included Dr. Octavian Henegariu, Dr. S. Bülent Omay,  Dr. Akdes Serin Harmancı, Mark W. Youngblood, Dr. Ketu Mishra-Gorur, Dr. Jie Li, Dr. Victoria E. Clark, , Dr. Alexander O. Vortmeyer, Dr. Kaya Bilguvar , Dr. Katsuhito Yasuno ,  Dr. Joachim Baehring , and Dr. Jennifer Moliterno. The study was performed in collaboration with clinicians at the Memorial Sloan Kettering Cancer Center in NY.

The study was funded by the Gregory Kiez and Mehmet Kutman Foundation


Top of Page

Cancer Issues
Latest Headlines

+ How Ovarian Cancer Spreads
+ What Stops Chinese Elderly From Using Preventive Care and Personalized Treatments for Cancer?
+ Grape-based Compounds Kill Colon Cancer Stem Cells in Mice
+ HPV Testing Leads to Earlier Detection and Treatment of Cervical Precancer
+ Patient Selection Key to Successful Immunotherapy
+ Underused Cancer Test Could Improve Treatment for Thousands
+ Throat Cancer Symptoms
+ How Mohs Surgery is Used to Fight Skin Cancer
+ Expedited Breast Cancer Treatment (VIDEO)
+ Treatment Puts the Freeze on Breast Cancer

Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions